Physician profile
Wilberto L Lopez
NPI 1275639544
$6,240.67
in general payments reported to CMS, 2019-2025
35 companies · $1,016 in 2025
The $1,016 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $554 · 2020: $741 · 2021: $747 · 2022: $1,261 · 2023: $841 · 2024: $1,081 · 2025: $1,016.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,938.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,937.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $819.33 | 2019-2025 | |
| Abiomed | $597.11 | 2022-2025 | Impella |
| Amgen INC. | $518.34 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $486.85 | 2019-2024 | Xarelto |
| Abbott Laboratories | $468.45 | 2019-2024 | Merlin@Home, Cardiomems |
| Cvrx, INC. | $348.43 | 2022-2023 | Barostim Neo System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $342.90 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $339.00 | 2021-2024 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $334.44 | 2021-2025 | Camzyos, Eliquis |
| Pfizer INC. | $247.12 | 2019-2025 | |
| Philips North America LLC | $178.41 | 2023-2025 | Azurion 7 M12, Extended Holter, Ecc Solutions |
| Medtronic, INC. | $169.49 | 2022 | |
| Esperion Therapeutics, INC. | $165.21 | 2020-2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $133.68 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $132.22 | 2020-2025 | Lifevest |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiovascular Systems INC. | $118.76 | 2020-2022 | |
| Shockwave Medical, INC | $102.91 | 2022 | |
| Amarin Pharma, INC. | $102.54 | 2020-2021 | |
| Impulse Dynamics (USA) INC. | $95.15 | 2022-2023 | Optimizer |
| Kestra Medical Technology Services, INC. | $91.89 | 2024-2025 | Assure Wcd |
| Astrazeneca Pharmaceuticals Lp | $60.84 | 2019-2025 | Wainua |
| Novo Nordisk INC | $50.31 | 2023-2024 | Ozempic |
| Regeneron Healthcare Solutions, INC. | $49.76 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $43.81 | 2023 | Inpefa |
| Arbor Pharmaceuticals, INC. | $37.68 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.71 | 2025 | |
| Bardy Diagnostics, INC. | $27.50 | 2020-2021 | |
| Actelion Pharmaceuticals US, INC. | $26.71 | 2025 | Uptravi |
| Astellas Pharma US INC | $19.60 | 2019 | |
| Cleerly, INC. | $19.48 | 2024 | Cleerly Labs, Cleerly Ischemia |
| Atricure, INC. | $19.36 | 2025 | Synergy Ablation System |
| Lilly USA, LLC | $18.14 | 2025 | Mounjaro, Zepbound |
| Azurity Pharmaceuticals, INC. | $17.59 | 2023 | Edarbi |
| Lundbeck LLC | $13.07 | 2020 | |
| Medtronic Vascular, INC. | $10.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wilberto Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.